Vortioxetine: First global approval

Drugs

Volumn 74, Issue 1, 2014, Pages 135-145

  Gibb, Andrew ^a   Deeks, Emma D ^b  

^a Adis R and D Insight   (New Zealand)

^b ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; ACETYLCHOLINE; DOPAMINE; GLUTAMIC ACID; HISTAMINE; NORADRENALIN; PLACEBO; SEROTONIN; VORTIOXETINE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; PIPERAZINE DERIVATIVE; SULFIDE;

ANTIDEPRESSANT ACTIVITY; ARTICLE; CANADA; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INTERACTION; DRUG METABOLISM; DRUG RECEPTOR BINDING; GENERALIZED ANXIETY DISORDER; HUMAN; MAJOR DEPRESSION; MAXIMUM PLASMA CONCENTRATION; NEUROTRANSMISSION; NONHUMAN; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); TRANQUILIZING ACTIVITY; UNITED STATES; ANIMAL; ANXIETY DISORDERS; CLINICAL TRIAL (TOPIC); DEPRESSIVE DISORDER, MAJOR; LEGISLATION AND JURISPRUDENCE;

ANIMALS; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANXIETY DISORDERS; CLINICAL TRIALS AS TOPIC; DEPRESSIVE DISORDER, MAJOR; DRUG APPROVAL; DRUG INTERACTIONS; HUMANS; PIPERAZINES; SULFIDES;

EID: 84893051321     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-013-0161-9     Document Type: Article

References (59)

1. Kennedy SH. A review of antidepressant therapy in primary care: current practices and future directions. Prim Care Companion CNS Disord. 2013;15(2).
2. Richelson E. Multi-modality: a new approach for the treatment of major depressive disorder. Int J Neuropsychopharmacol. 2013;16(6):1433-42.
3. H. Lundbeck AS and Takeda Pharmaceutical Company Limited. Takeda and Lundbeck announce FDA approval of Brintellix™ (vortioxetine) for treatment of adults with major depressive disorder [media release]. 01 Oct 2013. http://www.lundbeck.com.
4. Food and Drug Administration. NDA approval [letter]. 2013. http://www.accessdata.fda.gov/drugsatfda-docs/appletter/2013/204447Orig1s000ltr. pdf. Accessed 20 Nov 2013.
5. H. Lundbeck A/S and Takeda Pharmaceutical Co Ltd. Brintellix (vortioxetine) tablets, for oral use: US prescribing information; 2013. http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/204447s000lbl.pdf. Accessed 25 Oct 2013.
6. Lundbeck AS. FDA accepts Takeda and Lundbeck's filing for review of Brintellix (vortioxetine) for the treatment of major depression [media release]. 12 Dec 2012. http://www.lundbeck.com.
7. H. Lundbeck AS and Takeda Pharmaceutical Company Limited. Takeda and Lundbeck announce the submission of a New Drug Application for vortioxetine, an investigational drug for the treatment of major depression, in the US [media release]. 2 Oct 2012. http://www.lundbeck.com.
8. Lundbeck. Lundbeck files for regulatory approval of the novel multimodal antidepressant, vortioxetine, in Europe [media release]. 20 Sep 2012. http://www.lundbeck.com.
9. European Medicines Agency. Summary of opinion (initial authorisation): Brintellix, vortioxetine; 2013. http://www.ema.europa.eu/docs/en-GB/document- library/Summary-of-opinion-Initial-authorisation/human/002717/WC500153088.pdf. Accessed 31 Oct 2013.
10. H. Lundbeck AS. Third quarter report 2012: vortioxetine filed in the US and EU revenue from new products doubled [media release]. 6 Nov 2012. http://www.lundbeck.com.
11. Bang-Andersen B, Ruhland T, Jorgensen M, et al. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem. 2011;54(9):3206-21.
12. Areberg J, Luntang-Jensen M, Sogaard B, et al. Occupancy of the serotonin transporter after administration of Lu AA21004 and its relation to plasma concentration in healthy subjects. Basic Clin Pharmacol Toxicol. 2012;110(4):401-4.
13. Stenkrona P, Halldin C, Lundberg J. 5-HTT and 5-HT1A receptor occupancy of the novel substance vortioxetine (Lu AA21004). A PET study in control subjects. Eur Neuropsychopharmacol. 2013;23(10):1190-8.
14. Pehrson AL, Cremers T, Betry C, et al. Lu AA21004, a novel multimodal antidepressant, produces regionally selective increases of multiple neurotransmitters - a rat microdialysis and electrophysiology study. Eur Neuropsychopharmacol. 2013;23(2):133-45.
15. Mork A, Pehrson A, Brennum LT, et al. Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder. J Pharmacol Exp Ther. 2012;340(3):666-75.
16. Mork A, Brennum LT, Fallon S, et al. Pharmacological profile of Lu AA21004, a novel multi-target drug for the treatment of mood disorders [abstract no. P.2.d.017]. Eur Neuropsychopharmacol. 2009;19:S439.
17. Mork A, Montezinho LP, Miller S, et al. Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats. Pharmacol Biochem Behav. 2013;105:41-50.
18. Sanchez C, Pehrson AL, Betry C, et al. Vortioxetine (LU aa21004), an investigational multimodal antidepressant: differentiation from currently used antidepressants in preclinical rodent models [abstract]. Biol Psychiatry. 2013;73(9 Suppl 1):106S-7S.
19. Betry C, Pehrson AL, Etievant A, et al. The rapid recovery of 5-HT cell firing induced by the antidepressant vortioxetine involves 5-HT(3) receptor antagonism. Int J Neuropsychopharmacol. 2013;16(5):1115-27.
20. Riga MS, Celada P, Sanchez C, et al. Role of 5-HT3 receptors in the mechanism of action of the investigational antidepressant vortioxetine [abstract no. P.2.e.003]. Eur Neuropsychopharmacol. 2013;23 Suppl 2:S393-4.
21. Dale E, Zhang H, Leiser SC, et al. Vortioxetine (Lu AA21004) disinhibits pyramidal cell output and enhances theta rhythms and long-term plasticity in the hippocampus [abstract no. P.2.e.004]. Eur Neuropsychopharmacol. 2013;23 Suppl 2:S394.
22. Pehrson A, Li Y, Haddjeri N, et al. Vortioxetine, a novel multimodal antidepressant, modulates GABA and glutamate neurotransmission via serotonergic mechanisms [abstract no. P.1.g.014]. Eur Neuropsychopharmacol. 2013;23 Suppl 2:S196-7.
23. Du Jardin KG, Liebenberg N, Muller H, et al. Single dose vortioxetine or ketamine but not fluoxetine increases expression of neuroplasticity related genes in the rat prefrontal cortex [abstract no. P.2.e.001]. Eur Neuropsychopharmacol. 2013;23 Suppl 2:S392.
24. Guilloux J-P, Mendez-David I, Pehrson A, et al. Antidepressant and anxiolytic potential of the multimodal antidepressant vortioxetine (Lu AA21004) assessed by behavioural and neurogenesis outcomes in mice. Neuropharmacology. 2013;73:147-59.
25. Li Y, Raaby KF, Sanchez C, et al. Serotonergic receptor mechanisms underlying antidepressant-like action in the progesterone withdrawal model of hormonally induced depression in rats. Behav Brain Res. 2013;256:520-8.
26. Haddjeri N, Etievant A, Pehrson A, et al. Effects of the multimodal antidepressant Lu AA21004 on rat synaptic and cellular hippocampal plasticity and memory recognition [abstract no. P.2.h.002]. Eur Neuropsychopharmacol. 2012;22 Suppl 2:S303.
27. Leiser SC, Pehrson AL, Robichaud PJ, et al. Preclinical studies of the multimodal antidepressant vortioxetine support a potential for improvement of cognitive functions [abstract]. Neuropsychopharmacology. 2012;38:S164-5.
28. du Jardin KG, Jensen JB, Sanchez C, et al. Vortioxetine dose-dependently reverses 5-HT depletion-induced deficits in spatial working and object recognition memory: a potential role for 5-HT1A receptor agonism and 5-HT3 receptor antagonism. Eur Neuropsychopharmacol. 2013. doi: 10.1016/j.euroneuro. 2013.07.001.
29. Theunissen EL, Street D, Hojer AM, et al. A randomized trial on the acute and steady-state effects of a new antidepressant, vortioxetine (Lu AA21004), on actual driving and cognition. Clin Pharmacol Ther. 2013;93(6):493-501.
30. Wang Y, Nomikos GG, Karim A, et al. Effect of vortioxetine on cardiac repolarization in healthy adult male subjects: results of a thorough QT/QTc study. Clin Pharmacol Drug Dev. 2013;2(4):298-309.
31. Hojer AM, Sog B, Areberg J. Investigation of the absorption profile of Lu AA21004 [abstract no. P27]. Int J Psychiatry Clin Pract. 2011;15:25.
32. Mayer M, Xie J, Serenko M. Effect of formulation and food on the pharmacokinetics of Lu AA21004 in healthy subjects [abstract no. PII-49]. Clin Pharmacol Ther. 2012;91 Suppl 1:S69-70.
33. Areberg J, Sogaard B, Hojer A-M. The clinical pharmacokinetics of Lu AA21004 and its major metabolite in healthy young volunteers. Basic Clin Pharmacol Toxicol. 2012;111(3):198-205.
34. Uldam HK, Juhl M, Pedersen H, et al. Biosynthesis and identification of an N-oxide/N-glucuronide metabolite and first synthesis of an N-O-glucuronide metabolite of Lu AA21004. Drug Metab Dispos. 2011;39(12):2264-74.
35. Hvenegaard MG, Bang-Andersen B, Pedersen H, et al. Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004. Drug Metab Dispos. 2012;40(7):1357-65.
36. Dudkowski C, Lee R, Wu R, et al. A phase 1 study to assess the effect of age, gender and race on the pharmacokinetics of single and multiple doses of Lu AA21004 in healthy subjects [abstract no. PII-48]. Clin Pharmacol Ther. 2012;91 Suppl 1:S69.
37. Chen G, Lee R, Hojer A-M, et al. Pharmacokinetic drug interactions involving vortioxetine (Lu AA21004), a multimodal antidepressant. Clin Drug Investig. 2013;33(10):727-36.
38. Chen G, Lee R, Zhao Z, et al. A phase 1 study to assess the effect of LU AA21004 on the steady-state pharmacokinetics of lithium in healthy male subjects [abstract no. PI-84]. Clin Pharmacol Ther. 2012;91 Suppl 1:S39.
39. Lee RD, Wang Y, Zhao Z, et al. Effects of multiple doses of Lu AA21004 on the steady-state pharmacokinetics and pharmacodynamics of warfarin [abstract no. 1122787]. J Clin Pharmacol. 2011;51(9):1346.
40. Henigsberg N, Mahableshwarkar AR, Jacobsen P, et al. A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder. J Clin Psychiatry. 2012;73(7):953-9.
41. Baldwin DS, Loft H, Dragheim M. A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD). Eur Neuropsychopharmacol. 2012;22(7):482-91.
42. Mahableshwarkar AR, Jacobsen PL, Chen Y. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder. Curr Med Res Opin. 2013;29(3):217-26.
43. Jain R, Mahableshwarkar AR, Jacobsen PL, et al. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder. Int J Neuropsychopharmacol. 2013;16(2):313-21.
44. Katona C, Hansen T, Olsen CK. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol. 2012;27(4):215-23.
45. Mahableshwarkar A, Jacobsen PL, Serenko M, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of 2 doses of vortioxetine in adults with major depressive disorder [abstract no. NR9-02]. 166th annual meeting of the American Psychiatric Association; 18-22 May 2013; San Francisco.
46. Jacobsen P, Mahableshwarkar AR, Serenko M, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder [abstract no. NR9-06]. 166th annual meeting of the American Psychiatric Association; 18-22 May 2013; San Francisco.
47. Mahableshwarkar A, Jacobsen PL, Serenko M, et al. A duloxetine-referenced fixed dose study comparing efficacy and safety of 2 vortioxetine doses in the acute treatment of adult patients with MDD [abstract no. NR9-01]. 166th annual meeting of the American Psychiatric Association; 18-22 May 2013; San Francisco.
48. Haggstrom L, Nielsen RZ, Danchenko N, et al. A randomized, double-blind, study of vortioxetine versus agomelatine in adults with major depressive disorder (MDD) with inadequate response to SSRI/SNRI treatment [abstract no. P.2.f.029]. Eur Neuropsychopharmacol. 2013;23 Suppl 2:S412.
49. Boulenger JP, Loft H, Olsen CK. Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder. Int Clin Psychopharmacol. 2013. doi: 10.1097/YIC. 0000000000000018.
50. Boulenger J-P, Loft H, Florea I. A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder. J Psychopharmacol (Oxf). 2012;26(11):1408-16.
51. Baldwin DS, Hansen T, Florea I. Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder. Curr Med Res Opin. 2012;28(10):1717-24.
52. Alam MY, Jacobsen PL, Chen Y, et al. Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52-week extension study. Int Clin Psychopharmacol. 2013. doi: 10.1097/YIC.0000000000000010.
53. Filippov G, Christens PF. Vortioxetine (Lu AA21004) 15 and 20 mg/day: open-label long-term safety and tolerability in major depressive disorder [abstract no. P.2.b.011]. Eur Neuropsychopharmacol. 2013;23 Suppl 2:s325.
54. Alvarez E, Perez V, Dragheim M, et al. A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder. Int J Neuropsychopharmacol. 2012;15(5):589-600.
55. Florea I, Dragheim M, Loft H. The multimodal antidepressant Lu AA21004: open-label long-term safety and tolerability study in major depressive disorder [abstract no. P.2.c.010]. Eur Neuropsychopharmacol. 2012;22 Suppl 2:S255-6.
56. Bidzan L, Mahableshwarkar AR, Jacobsen P, et al. Vortioxetine (Lu AA21004) in generalized anxiety disorder: results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial. Eur Neuropsychopharmacol. 2012;22(12):847-57.
57. Rothschild AJ, Mahableshwarkar AR, Jacobsen P, et al. Vortioxetine (Lu AA21004) 5 mg in generalized anxiety disorder: results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States. Eur Neuropsychopharmacol. 2012;22(12):858-66.
58. Baldwin DS, Loft H, Florea I. Lu AA21004, a multimodal psychotropic agent, in the prevention of relapse in adult patients with generalized anxiety disorder. Int Clin Psychopharmacol. 2012;27(4):197-207.
59. Lundbeck AS. Lundbeck announces positive results for Brintellix (vortioxetine) in adult patients with major depression and inadequate response to SSRI or SNRI therapy [media release]; 2013. http://www.lundbeck.com.